MCL Literature Feed

This phase 2 study of frontline acalabrutinib, lenalidomide, and anti-CD20 demonstrates high molecular response rates (67-90%) and 76% 4-year PFS, supporting a time-limited, MRD-driven, chemotherapy-free treatment strategy.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This US real-world study describes treatment patterns and outcomes for covalent BTK inhibitors in relapsed/refractory MCL, providing crucial benchmarks for routine clinical practice outside of trial settings.

This case report describes follicular lymphoma of the larynx and is not relevant to mantle cell lymphoma research or clinical practice.

This case report identifies fingertip fissures as a rare dermatologic toxicity of ibrutinib in an elderly MCL patient, expanding the known adverse event profile for this common therapy.

The HSP90-MYC-CDK9 molecular network is identified as a key driver of therapeutic resistance in MCL, suggesting HSP90 or CDK9 inhibitors as potential strategies to overcome it.

This report summarizes the 2025 LRF MCL Workshop, highlighting key research developments in pathogenesis, resistance, and novel therapies, thereby setting the agenda for future clinical and translational research.

High expression of the lncRNA MALAT1 is a novel, independent biomarker for favorable prognosis in MCL, inversely correlating with proliferation signatures and EZH2 activity.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

This retrospective study found one case of occult mantle cell lymphoma in 1328 adult tonsillectomies for benign indications, underscoring the value of routine histopathology for unexpected diagnoses.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.

This review positions CAR-T and bispecific antibodies as complementary tools for relapsed/refractory MCL, advocating for individualized sequencing and combinations to optimize outcomes in heavily pretreated, high-risk patients.

The combination of acalabrutinib with bendamustine-rituximab is evaluated as a frontline therapy for elderly MCL patients, aiming to improve outcomes over standard chemoimmunotherapy.

A novel fluorescence-based assay quantifies pirtobrutinib in biological fluids, potentially enabling therapeutic drug monitoring to optimize dosing, manage toxicity, and study resistance in MCL patients.

This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.

This case report describes the rare co-occurrence of MCL and CLL/SLL, highlighting the diagnostic and therapeutic challenges that require careful pathologic evaluation to guide appropriate treatment.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.

Flow cytometry is crucial for accurately diagnosing leukemic-phase blastoid MCL, resolving morphological ambiguity with other acute leukemias and ensuring correct treatment for this aggressive variant.

This bioinformatic study identified a prognostic network of six circular RNAs in mantle cell lymphoma that regulate key pathways like BCR signaling, suggesting their potential as novel biomarkers.

Real-world data from an Italian compassionate use program confirms pirtobrutinib's efficacy in heavily pre-treated, relapsed/refractory MCL, including patients who have failed prior covalent BTK inhibitors.

This review outlines the historical evolution in understanding transformed mantle cell lymphoma, highlighting changes in its pathological diagnosis, genomic drivers, and the clinical challenges it presents.

This preclinical development of an optimized CXCR4-targeting theranostic pair offers a novel strategy to simultaneously image and treat MCL by targeting a key pathway in aggressive disease.

This case report details a rare, life-threatening presentation of MCL with massive pleural effusions requiring mechanical ventilation, highlighting a severe form of serosal involvement and its management.

Co-expression of PD-L1/PD-1 with CXCR3 and systemic inflammation indices (SIRI, SII) identified advanced stage and poor survival in a mixed lymphoma cohort, offering potential prognostic biomarkers for MCL.

This review summarizes cutaneous toxicities across different BTK inhibitors, highlighting the improved skin safety profile of newer agents, which is critical for managing long-term MCL therapy.

This study demonstrates that TP53 mutation heterogeneity, not just presence, defines distinct prognostic subgroups in MCL, enabling more precise risk stratification beyond a simple binary classification.

Long-read sequencing systematically identifies novel fusion transcripts in MCL, potentially revealing new prognostic biomarkers and therapeutic targets beyond the canonical t(11;14) translocation.

In a real-world French cohort, MCL patients failing CAR-T therapy have dismal outcomes (median OS 5.8 months), highlighting an urgent need for effective salvage, with bispecific antibodies showing promise.

This review outlines the evolution of BTK inhibitors, highlighting how non-covalent agents like pirtobrutinib overcome C481-mediated resistance, extending the therapeutic sequence for relapsed/refractory MCL.